Azitra, Inc.
AZTR NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.53
KIRA · Stoqly’s AI analyst, in plain words
- Azitra, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Azitra, Inc. lost $11.0M in fiscal 2025.
- Free cash flow was −$11.2M in fiscal 2025, — of revenue.
Market cap
$29.5M
P/E
25.5x
Revenue
$0.0M
Net income
−$11.0M
Free cash flow
−$11.2M
Operating margin
—
Azitra, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$11.0M
No. It lost money last year.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
25.5x
One share costs 25.5 times its yearly profit per share.
What Azitra, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Azitra, Inc.
- CIK
- 0001701478
Azitra, Inc. · AZTR
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.3M | $0.7M | $0.0M | $0.0M |
| Revenue growth | — | 141.5% | −98.9% | −100.0% |
| Operating margin | −3,328.7% | −1,086.1% | −146,468.0% | — |
| Net income | −$10.7M | −$11.3M | −$9.0M | −$11.0M |
| Net margin | −3,760.7% | −1,644.9% | −119,566.7% | — |
| Diluted EPS | −$12.74 | −$54.98 | −$15.70 | −$2.25 |
| Cash | ||||
| Cash from operations | −$8.3M | −$7.4M | −$10.2M | −$11.2M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.4M | −$7.4M | −$10.2M | −$11.2M |
| FCF margin | −2,951.6% | −1,077.1% | −135,897.3% | — |
| Share count change | — | −78.2% | 148.5% | 753.2% |
| Debt and strength | ||||
| Cash and short-term investments | $3.5M | $1.8M | $4.6M | $2.1M |
| Shareholders' equity | −$36.3M | $2.9M | $5.7M | $3.8M |
| Current ratio | 1.9x | 1.6x | 3.8x | 2.8x |
| Interest coverage | −37.5x | −44.4x | −900.4x | −1,443.0x |
| Returns and quality | ||||
| Return on equity | — | — | −208.3% | −230.7% |
| Return on tangible equity | — | −467.7% | −164.5% | −314.4% |
| Piotroski F-score | — | 3 | 2 | 0 |
| Altman Z'' | −28.0 | −38.2 | −28.5 | −53.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Azitra, Inc. · AZTR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.53 a share, the company is worth $29.5M: 25.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001701478). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.